Cytogenetic profiles as additional markers to pathological features in clinically localized prostate carcinoma

Cancer Letters

Volumn 237, Issue 1, 2006, Pages 76-82

  Gallucci, Michele ^a   Merola, Roberta ^a   Farsetti, Antonella ^b   Orlandi, Giulia ^a   Sentinelli, Steno ^a   De Carli, Piero ^a   Leonardo, Costantino ^a   Carlini, Paolo ^a   Guadagni, Fiorella ^a   Sperduti, Isabella ^a   Cianciulli, Anna Maria ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b CNR   (Italy)

Author keywords

FISH; Genetic markers; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; LIPOPROTEIN LIPASE;

ARTICLE; CHROMOSOME 7; CHROMOSOME 8; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GLEASON SCORE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; STATISTICAL ANALYSIS; X CHROMOSOME;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 7; CHROMOSOMES, HUMAN, PAIR 8; CHROMOSOMES, HUMAN, X; CYTOGENETIC ANALYSIS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LIPOPROTEIN LIPASE; LYMPH NODE EXCISION; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR MARKERS, BIOLOGICAL;

EID: 33646511541     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.05.033     Document Type: Article

References (22)

1. Cairns P., Okami K., Halachmi N., Esteller M., Herman J.G., Jen J., et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57 (1997) 4997-5000
2. Abate-Shen C., and Shen M.M. Molecular genetics of prostate cancer. Genes Dev. 14 (2000) 2410-2434
3. Elo J.P., and Visakorpi T. Molecular genetics of prostate cancer. Ann. Med. 33 (2001) 130-141
4. Tsuchiya N., Slezak J.M., Lieber M.M., Bergstralh E.J., and Jenkins R.B. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer 34 (2002) 363-371
5. Matsuyama H., Pan Y., Oba K., Yoshihiro S., Matsuda K., Hagarth L., et al. Deletions on chromosome 8p21 may predict disease progression as well as pathological staging in prostate cancer. Clin. Cancer Res. 7 (2001) 3139-3143
6. Bostwick D.G., Shan A., Qian J., Darson M., Mailhle N.J., Jenkins R.B., and Cheng L. Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer 83 (1998) 1995-2002
7. Nupponen N.N., Kakkola L., Koivisto P., and Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am. J. Pathol. 153 (1998) 141-148
8. Jenkins R., Takahashi S., De Lacey K., Bergstralh E., and Lieber M. Prognostic significance of allelic imbalance of chromosome arms 7q, 8p,16q and 18q in stage T3N0M0 prostate cancer. Genes Chromosomes Cancer 21 (1998) 131-143
9. Amati B., Alevizopoulos K., and Vlach J. Myc and the cell Cycle. Front. Biosci. 3 (1998) D250-D268
10. Palmerg C., Koivisto P., Kakkola L., Tammela T.L.J., Kallioniemi O.P., and Visakorpi T. Androgen receptor gene amplification at the time of primary progression predicts response to combined androgen blockade as a second-line therapy in advanced prostate cancer. J. Urol. 164 (2000) 1992-1995
11. Ye D., Mendelsohn J., and Fan Z. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27 and costimulate proliferation of MDA PCA 2a and MDA PCA 2b prostate cancer cells. Clin. Cancer Res. 5 (1999) 2171-2177
12. Di Lorenzo G., Tortora G., D'Armiento F.P., De Rosa G., Staibano S., Autorino R., et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res. 8 (2002) 3438-3444
13. UICC. TNM Classification of Malignant Tumors. sixth ed. (2002), Wiley-Liss, New York
14. Cianciulli A.M., Leonardo C., Guadagni F., Marzano R., Iori F., De Nunzio C., et al. Genetic instability in superficial bladder cancer and adjacent mucosa: an interphase cytogenetic study. Hum. Pathol. 34 (2003) 214-221
15. Trapasso J., deKernion J., Smith R., and Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol. 152 (1994) 1821-1825
16. Alers J.C., Rochat J., Krijtenburg P.J., Hop W.C.P., Krance R., Rosenberg C., et al. Identification of genetic markers for prostate cancer progression. Lab. Invest. 80 (2000) 931-942
17. Alers J.C., Krijtenburg P.J., Vis A.N., Hoedemaeker R.F., Wildhagen M.F., Hop W.C.P., et al. Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: early cancers may contain aggressive genetic features. Am. J. Pathol. 158 (2001) 399-406
18. 0 prostate cancer are potential markers for cancer progression. Mod. Pathol. 15 (2002) 35-44
19. Hermes E., Fossa S.D., Berner A.A., Otnes B., and Nesland J.M. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br. J. Cancer 90 (2004) 449-454
20. van Dekken H., Alers J.C., Damen I.A., Vissers K.J., Krijtenburg P.J., Hoedemaeker R.F., et al. Genetic evaluation of localized prostate cancer in a cohort of forty patients: gain of distal 8q discriminates between progressors and nonprogressors. Lab. Invest. 83 (2003) 789-796
21. Kaltz-Wittmer C., Klenk U., Glaessgen A., Aust D.E., Diebold J., Lohrs U., and Baretton G.B. FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab. Invest. 80 (2000) 1455-1464
22. Sato K., Qian J., Slezak J.M., Lieber M.M., Bostwick D.G., Bergstralh E.J., and Jenkins R.B. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J. Natl Cancer Inst. 91 (1999) 1574-1580